This trial looks at using a medicine called APL-101 to treat advanced non-small cell lung cancer (NSCLC) that has certain genetic changes. It aims to see how well APL-101 works alone and when combined with other treatments. Participants will be grouped based on their specific type of cancer and previous treatments.
The trial's ID number is NCT03175224. It is a Phase 2 trial, meaning it is looking at how well APL-101 works and how safe it is. It is FDA-regulated and aims to include about 497 participants.
Who can join
Men and women ages 18 and older can join. There are several groups based on their cancer type and treatment history. Some must not have had any MET inhibitor treatment before. The trial team will check eligibility before anyone can join.
The study team makes the final call on eligibility.
What happens in the study
Participants will take APL-101 capsules by mouth. They will be placed into groups based on their cancer type and treatment history. Some will receive APL-101 alone, while others may receive it with standard treatments. Everyone will be monitored for how well the treatment works.
Where
This trial is enrolling at 6 locations. Recruiting sites are listed first.
Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.